Vascular effects of sustained-release fibroblast growth factors

David B. Hom, Khawar Medhi, Girma Assefa, Steven K. Juhn, Thomas P. Johnston

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Since the half-life of most angiogenic growth factors is several hours or less, sustained-release delivery would be optimal for their future clinical use. Two fibroblast growth factors, basic fibroblast growth factor (bFGF) and endothelial cell growth factor (ECGF), were delivered in two sustained- released modalities (poloxamer 407 and a gelatin sponge [Gelfoam]) to attempt to increase soft tissue vascularity. In vitro bioactivity of ECGF-poloxamer formulations was also tested on endothelial cell cultures. Among vascular- compromised skin flaps in rabbits, ECGF-poloxamer (N = 26), bFGF-poloxamer (N = 5), ECGF-poloxamer (N = 9, irradiated), and bFGF-Gelfoam flaps (N = 22) did not demonstrate significant differences in viability and vascularity compared to controls (p > .05). Irradiation had a detrimental effect on both flap vascularity and viability (p = .02). Future efforts for sustained delivery of angiogenic proteins are critical in order to make them clinically useful in wound healing.

Original languageEnglish (US)
Pages (from-to)109-116
Number of pages8
JournalAnnals of Otology, Rhinology and Laryngology
Issue number2
StatePublished - Feb 1996

Bibliographical note

Copyright 2017 Elsevier B.V., All rights reserved.


  • growth factors
  • neovascularization
  • surgical flaps
  • wound healing


Dive into the research topics of 'Vascular effects of sustained-release fibroblast growth factors'. Together they form a unique fingerprint.

Cite this